Timing of thoracic radiotherapy combined with immunotherapy influences pulmonary injury

Yuan,Jing; Liu,Qiteng; Liu,Xuan; Zheng,Xianbin; Nan,Xianxiu; Shi,Xinjue; Zhong,Siyao; Sun,Bin; Hao,Pan; Wang,Sen; Gao,Yuyan

doi:10.3892/ol.2025.14953

Timing of thoracic radiotherapy combined with immunotherapy influences pulmonary injury

Authors:
- Jing Yuan
- Qiteng Liu
- Xuan Liu
- Xianbin Zheng
- Xianxiu Nan
- Xinjue Shi
- Siyao Zhong
- Bin Sun
- Pan Hao
- Sen Wang
- Yuyan Gao
View Affiliations

Affiliations: Department of Radiation Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China, Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China, Department of Neurosurgery, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China
Published online on: March 4, 2025 https://doi.org/10.3892/ol.2025.14953
Article Number: 206
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the impact of chest radiotherapy combined with immunotherapy at different time points in lung injury. This retrospective study analyzed 35 patients with thoracic tumors (29 lung cancer cases and 6 esophageal cancer cases) who received radiotherapy combined with immunotherapy between January 2021 and December 2023 at at Capital Medical University, affiliated with Beijing Luhe Hospital (Beijing, China), with a median follow‑up time of 21 months. Patients were divided into two groups: Group A (sequential, n=17), who received immunotherapy 2 weeks to 6 months before or after radiotherapy, and group B (synchronous, n=18), who received immunotherapy within 2 weeks before or after radiotherapy. Furthermore, the incidence and severity of lung injury, especially pneumonitis, were also compared. Moreover, risk factors for lung injury, as well as 3‑year overall survival (OS) rates for stage III and IV lung cancer, were evaluated. There were no significant differences in tumor location, stage, age, tumor type, Eastern Cooperative Oncology Group score or sex between groups. The proportion of PD‑1 in group A was higher, while the proportion of PD‑L1 was lower, compared with that in group B. Furthermore, radiotherapy techniques and dosimetric parameters were also similar. Moreover, there were no significant differences in onset time between esophagitis, anemia or pneumonitis between the two groups. However, incidence of grade 3 or higher pneumonitis was 0.0% in the sequential group and 23.5% in the synchronous group, which was significantly different. Univariate analysis identified lung mean dose and the percentage volume receiving ≥30 Gy (V30) as significant risk factors, whereas multivariate analysis revealed that V30 was an independent prognostic factor. The 3‑year OS rates for stage III and IV lung cancer were 44.8 and 22.5%, respectively. In conclusion, the present study revealed that radiotherapy combined with immunotherapy increases the survival rate; however, it also elevates the risk of grade 3+ pneumonitis, especially within 2 weeks of concurrent therapy. As pneumonia occurs at around 3 months after radiotherapy, a follow‑up time of 2‑4 months post‑treatment is recommended.

View Figures

View References

1	National Comprehensive Cancer Network (NCCN), . Non-Small Cell Lung Cancer (NCCN Guidelines^®). NCCN; Plymouth Meeting, PA: 2024
2	Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, et al: Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 13:eabb36312021. View Article : Google Scholar : PubMed/NCBI
3	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al: PACIFIC investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
4	Stucci S, Palmirotta R, Passarelli A, Silvestris E, Argentiero A, Lanotte L, Acquafredda S, Todisco A and Silvestris F: Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management. Oncol Lett. 14:5671–5680. 2017.PubMed/NCBI
5	Wang CL, Ho AS and Cheng CC, Sie ZL, Peng CL, Chang J and Cheng CC: Radiotherapy enhances CXCR3^highCD8⁺ T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells. Cancer Immunol Immunother. 72:1865–1880. 2023. View Article : Google Scholar : PubMed/NCBI
6	U.S. Department of Health and Human Services, . Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0).
7	Chang W: R Graphics Cookbook. O'Reilly Media; 2013
8	Goldstraw P, Crowley J, Chansky K, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 10:1260–1271. 2015.
9	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
10	Shaverdian N, Lisberg AE, Bomazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 8:895–903. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ross GM: Induction of cell death by radiotherapy. Endocr Relat Cancer. 6:41–44. 1999. View Article : Google Scholar : PubMed/NCBI
12	Vinod SK and Hau E: Radiotherapy treatment for lung cancer: Current status and future directions. Respimlogy. 25 (Suppl 2):S61–S71. 2020. View Article : Google Scholar
13	Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gómez L, Verginadis I, Bittinger K, Pustylnikov S, Pierini S, Perales-Linares R, Blair IA, et al: Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest. 130:466–479. 2020. View Article : Google Scholar : PubMed/NCBI
14	Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, Li S, Xue P, Wang G, Sun Y, et al: Efficacy and safety of first-line lmmunotherapy combinations for advanced NSCLC: A systematic review and network meta-analysis. J Thorac Oncol. 16:1099–1117. 2021. View Article : Google Scholar : PubMed/NCBI
15	Hen'era FG, Irving M, Kandalaft LE and Coukos G: Rational combinations of immunotherapy with radiotherapy inovarian cancer. Lancet Oncol. 20:e417–e433. 2019. View Article : Google Scholar
16	Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH and Hodi F: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol. 2:1607–1616. 2016. View Article : Google Scholar : PubMed/NCBI
17	Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB, Bradley JD, et al: Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer. J Clin Oncol. 37:85112019. View Article : Google Scholar
18	Lu X, Wang J, Zhang T, Zhou Z, Deng L, Wang X, Wang W, Liu W, Tang W, Wang Z, et al: Comprehensive pneumonitis profile of thoracic radiotherapy followed by immune checkpoint inhibitor and risk factors for radiation recall pneumonitis in lung cancer. Front Immunol. 13:9187872022. View Article : Google Scholar : PubMed/NCBI
19	Huang HY, Gong HY and Song QB: Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy. J Int Oncol. 50:102–106. 2023.(In Chinese).
20	Chen K and Sun B: Incidence and risk of PD-1/PD-L1 inhibitor-associated pneumonia in advance cancer patients: A meta-analysis. Zhongguo Fei Ai Za Zhi. 23:927–940. 2020.(In Chinese). PubMed/NCBI
21	Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, et al: Immune checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 50:17000502017. View Article : Google Scholar : PubMed/NCBI
22	Lu XT, Wang JY, Zhang T, Zhou Z, Deng L, Wang X, Wang W, Liu W, Tang W, Wang Z, et al: Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer. Front Immunol. 13:9187872022. View Article : Google Scholar : PubMed/NCBI
23	Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, et al: Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON). J Clin Oncol. 38:90392020. View Article : Google Scholar
24	Chen Y, Liu X, Huang Z, Zhao K, Wang Y, Ren F, Yu J and Meng X: Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. Cancer Med. 10:8518–8529. 2021. View Article : Google Scholar : PubMed/NCBI
25	Lin SH, Lin Y, Yao L, Kalihor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, et al: Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 15:248–257. 2020. View Article : Google Scholar : PubMed/NCBI